Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O8SJ
|
|||
| Former ID |
DIB001963
|
|||
| Drug Name |
Umbralisib
|
|||
| Synonyms |
RP5264; TGR-1202
Click to Show/Hide
|
|||
| Indication | Follicular lymphoma [ICD-11: 2A80; ICD-9: 202] | Approved | [1] | |
| Marginal zone lymphoma [ICD-11: 2A85.0; ICD-10: C88.7] | Approved | [1] | ||
| Diffuse large B-cell lymphoma [ICD-11: 2A81; ICD-10: C83.3; ICD-9: 200] | Phase 2/3 | [2] | ||
| Chronic lymphocytic leukaemia [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Phase 2 | [3] | ||
| Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C85.9] | Phase 2 | [3] | ||
| Company |
Tg therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C31H24F3N5O3
|
|||
| Canonical SMILES |
CC(C)OC1=C(C=C(C=C1)C2=NN(C3=NC=NC(=C23)N)C(C)C4=C(C(=O)C5=C(O4)C=CC(=C5)F)C6=CC(=CC=C6)F)F
|
|||
| InChI |
1S/C31H24F3N5O3/c1-15(2)41-24-9-7-18(12-22(24)34)27-26-30(35)36-14-37-31(26)39(38-27)16(3)29-25(17-5-4-6-19(32)11-17)28(40)21-13-20(33)8-10-23(21)42-29/h4-16H,1-3H3,(H2,35,36,37)/t16-/m0/s1
|
|||
| InChIKey |
IUVCFHHAEHNCFT-INIZCTEOSA-N
|
|||
| CAS Number |
CAS 1532533-67-7
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021 | |||
| REF 2 | ClinicalTrials.gov (NCT02793583) Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma (UNITY-NHL). U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.